Malignant melanoma is the most deadly of all skin cancers. Despite its lethality, no targeted topical chemopreventive agents exist to inhibit this cancer in its earliest forms or when cells are present in the lymphatic system in the proximity of the early primary lesion. Among possible chemopreventive targets is Akt3 whose activity increases in ~70% of tumors to promote melanoma development. Targeting early melanocytic lesion cells using siRNA-based agents to inhibit Akt3 and other key kinases could be important for targeted melanoma chemoprevention, but delivery of siRNA remains a challenge. Currently, no technology or approach utilizes siRNA as a chemopreventive agent to inhibit early melanoma development. This application focuses on melanoma chemoprevention by targeting early melanocytic lesions using siRNA-based agents to inhibit Akt3 and mutant V600EB-Raf, GSK31 or Wee1 kinases, which are shown to synergistically inhibit melanocytic lesion cells. Thus, the central hypothesis for the proposed research is that siRNA targeting Akt3 and mutant V600EB-Raf, GSK31 or Wee1 kinases can be delivered via novel ultrasound-nanoliposomal technology into skin containing early melanocytic lesions to prevent melanoma development and invasion of these cells into or through the lymphatic system. The rationale is that siRNA targeting these genes would serve as pathway specific targeted chemopreventive agents to prevent melanoma development. We formulated this hypothesis based on proof-of-principal preliminary discoveries identifying kinases to target that can synergise with Akt3 inhibition. Furthermore, we show that siRNA against Akt3 and V600EB-Raf can be loaded into nanoliposomes and placed on skin containing melanocytic lesions following ultrasound treatment, effectively inhibiting melanoma cell survival, and if delivered together it can cooperatively prevent disease development. Thus, the objectives of this application are to first, evaluate the chemopreventive efficacy of novel nanoliposomes containing siRNA-targeting Akt3 and mutant V600EB-Raf, GSK31 or Wee1 kinases in a transgenic animal model of the disease in which both Akt3 and V600EB-Raf are deregulated to promote spontaneous melanocytic lesion development. This will be accomplished by loading siRNA targeting Akt3 and V600EB-Raf, GSK31 or Wee1 into antibody-targeted nanoliposomes and following ultrasound treatment, effectively deliver agents into spontaneously developing early melanocytic lesions in skin of animals. Second, we will determine whether these agents can prevent or decrease lymph node invasion by early melanocytic cells to decreased disease development and aid survival. This will be accomplished by treating mice with nanoliposomal siRNA prior to or following invasion of the lymph node basin by melanocytic lesion cells to establish whether it will prevent disease progression. Delivery of siRNA against key kinases using an antibody-targeted nanoliposomal formulation following ultrasound-mediated skin permeabalization is a novel approach critically needed for more effective chemoprevention of melanoma and inhibition of its spread into and through the lymphatic system.

Public Health Relevance

Over the long-term, discovery of targeted chemopreventive agents that inhibit kinases involved in melanocytic lesion development are predicted to significantly decrease melanoma incidence rates. Specifically, development of this nanoscale antibody-targeted chemopreventive agent would have significant potential to impact human health by decreasing the number of people developing this disease, thereby directly decreasing mortality rates from melanoma. Therefore, the positive impact of this study for preventing melanoma would be significant.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA136667-03
Application #
8209300
Study Section
Chemo/Dietary Prevention Study Section (CDP)
Program Officer
Perloff, Marjorie
Project Start
2010-03-12
Project End
2014-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
3
Fiscal Year
2012
Total Cost
$407,854
Indirect Cost
$117,602
Name
Pennsylvania State University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
129348186
City
Hershey
State
PA
Country
United States
Zip Code
17033
Kardos, Gregory R; Dai, Mu-Shui; Robertson, Gavin P (2014) Growth inhibitory effects of large subunit ribosomal proteins in melanoma. Pigment Cell Melanoma Res 27:801-12
Kuzu, Omer F; Gowda, Raghavendra; Sharma, Arati et al. (2014) Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport. Mol Cancer Ther 13:1690-703
Mumford, Brigid S; Robertson, Gavin P (2014) Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential. Mol Diagn Ther 18:175-83
Gowda, Raghavendra; Madhunapantula, SubbaRao V; Kuzu, Omer F et al. (2014) Targeting multiple key signaling pathways in melanoma using leelamine. Mol Cancer Ther 13:1679-89
Gowda, Raghavendra; Madhunapantula, SubbaRao V; Sharma, Arati et al. (2014) Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma. Mol Cancer Ther 13:2328-40
Sharma, Arati; Madhunapantula, SubbaRao V; Gowda, Raghavendra et al. (2013) Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma. Am J Pathol 182:1151-62
Madhunapantula, SubbaRao V; Sharma, Arati; Gowda, Raghavendra et al. (2013) Identification of glycogen synthase kinase 3* as a therapeutic target in melanoma. Pigment Cell Melanoma Res 26:886-99
Gowda, Raghavendra; Madhunapantula, Subbarao V; Desai, Dhimant et al. (2013) Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma. Mol Cancer Ther 12:3-15
Sharma, Arati; Madhunapantula, SubbaRao V; Robertson, Gavin P (2012) Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opin Drug Metab Toxicol 8:47-69